Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45

Report documents

1. Addendum

   Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45

   published on

   01.12.2023

   Document type

   PDF document, 258 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G23-25_V1.1

   Download file : Addendum (PDF document, 258 kB, DE, not accessible)

Additional information

Project details

Project no.

G23-25

Commission

Commission awarded on 26.09.2023 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

The current version 1.1 of the addendum replaces version 1.0 published on 2023-11-17.

DOI

https://dx.doi.org/10.60584/G23-25_V1.1

Connected Projects

1. Dossier assessment

   Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V

   Project no.

   A23-45

   Last updated

   17.11.2023

   Status: Commission completed